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Abstract: 
Trial-based economic evaluations are an important aspect of health technology assessment. The 
availability of patient-level data coupled with unbiased estimates of clinical outcomes means that 
randomised controlled trials are effective vehicles for the generation of economic data. However 
there are methodological challenges to trial-based evaluations, which include the collection of 
reliable data on resource use and cost, choice of health outcome measure, calculating minimally 
important differences, dealing with missing data, extrapolating outcomes and costs over time and 
the analysis of multinational trials. This review focuses on the state of the art of selective elements 
concerning the design, conduct, analysis and reporting of trial-based economic evaluations. The 
limitations of existing approaches are detailed and novel methods introduced. The review is 
internationally relevant but with a focus towards practice in the UK. 
Key Messages: 
 Trial-based economic evaluations require careful consideration of design, conduct, analysis and 
reporting. 
 Areas for improvement include the need for more robust methods to estimate resource 
utilisation, use of multiple imputation for missing data, and application of appropriate modelling 
for the assessment of the impact of non-adherence.  
 This review identifies economic methods that may also enhance clinical trials such as for 
calculating minimally important differences using discrete choice experiments, and undertaking 
data extrapolation based on modelling. 
 
1. Introduction 
Randomised controlled trials (RCTs) are an important foundation for economic evaluation. RCTs 
generate patient-level data that provide an unbiased estimate of the efficacy or effectiveness of an 
intervention being tested, as well as an opportunity for collecting resource use and cost data 
necessary for calculating an intervention’s cost-effectiveness. RCTs, however, are not a panacea and 
rarely do they provide the full information necessary for an economic evaluation or to inform a 
decision [1]. Approaches to trial-based economic evaluation have consequently evolved, as detailed 
in recent guidelines and reviews [2-4]. This article focuses on specific aspects of trial-based 
evaluations where there is scope for improvement and introduces novel methodologies that may 
complement or supplant current approaches. The topics discussed can be broadly categorised into 
the methods of interpreting trial-based data, and techniques for using trial-based data in model-
based evaluation. The former category considers methods for resource use estimation, choice of 
outcome measure, handling missing data, accounting for patient non-adherence and analysis of 
multi-national trial data. Factors relating to the application of trial-based data in modelling include 
consideration and discussion of issues on calculating minimally-important differences and methods 
for extrapolation. Based on a purposive review of the literature, the concepts discussed are 
internationally relevant but with a focus towards practice in the UK. 
2. Trial-based economic evaluations 
2.1. When to conduct economic evaluation? 
Several factors signpost the need to undertake an economic evaluation, including:  
3 
 
Anticipated difference in therapeutic benefit between interventions. New health technologies are 
less likely to be cost-effective (and thus more reason to conduct an economic analysis) if any 
difference in health outcome is anticipated to be small when compared with existing interventions. 
Large cost differences. An economic analysis is warranted if the new health technology is potentially 
very costly and /or the two (or more) interventions being compared are of greatly different cost; or, 
if there are considerable down-stream costs that occur or continue beyond the trial time horizon, 
that may differ between interventions such as increased intensity of care or frequency of testing. 
High levels of uncertainty around the cost-effectiveness, or economic impact of health technology; 
the greater the uncertainty, the stronger the case for economic evaluation.  
Sizeable budget impact as a result of a potentially large population or population subgroup. Health 
economic analyses may be less appropriate if the decision rule is based on budget impact and the 
overall budgetary impact is very small, as the opportunity cost associated with an incorrect decision 
may be limited.  
2.2. Does the economic evaluation need to be based on RCT evidence?  
Where an economic evaluation is indicated, it is imperative that due consideration is given as to 
whether an RCT is the most suitable platform for evidence acquisition. Decisions may have to be 
made before results are available from clinical trials; or put another way, the value of generating 
economic evidence from a clinical trial might be less than the costs of postponing a decision. In such 
circumstances, an economic model may be preferred. Trials which include comparators that differ 
from routine care, include selective sub-populations of patients, or which are not pragmatic in 
design may not lead to reliable estimates of the comparative effectiveness of treatments, and may 
therefore bias the cost-effectiveness result. 
Organisations such as the UK National Institute for Health Research Health Technology Assessment 
(NIHR-HTA) programme, aim to inform clinical decisions by funding pragmatic studies that address 
issues of clinical and cost effectiveness. A review of 78 randomised studies funded by the NIHR-HTA 
programme published to June 2009, identified 75 (96%) of studies to include an economic analysis 
[5]. However not all trials are amenable to economic analysis, and not all interventions require trial-
based economic evidence. It may be the case, for instance, that the intervention is low cost but non-
inferior to current practice. While this might only be known ex post, there are specific instances 
where RCTs are less relevant for economic evaluations. A trial-based economic evaluation would be 
unnecessary in the case of a comparison of two similar interventions that are delivered in different 
settings, whereby incremental benefits might mean less use of expensive resources. The cost of 
either saline or albumin for resuscitation in patients with severe sepsis, for instance, is dwarfed by 
the potential savings from a reduction in expensive intensive care should one prove to be more 
effective. Cost would not be a factor to influence the decision to change clinical practice. Economic 
evaluation can also, in the appropriate situation, take data from non-RCT sources. For example, a 
cost-minimisation analysis comparing endometrial ablation performed as a day case under general 
anaesthesia or as an outpatient using local anaesthetic used hospital data that were routinely 
collected [6]. Similarly, a cost-minimisation analysis, for instance, would be appropriate without the 
need to source economic evidence directly from trials of generic medicines that are bioequivalent to 
their branded counterparts. 
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2.3. Modelling of RCT data, or a trial-based evaluation? 
It is generally accepted that some form of economic evaluation is necessary to support funding 
decisions on new healthcare interventions. However, it is important to note that only a small 
proportion of healthcare interventions and services are prioritised for appraisal by HTA 
organisations. The National Institute for Health and Care Excellence (NICE) in the UK expect an 
economic model to form part of the assessment, but whether this is a trial-based economic 
evaluation is not a high priority [7].  
A model can flexibly evaluate different patient populations, sub-groups, interventions, outcomes, 
resources and cost effects. Such an approach is almost always justified in order to synthesise the 
evidence base and to take into account the uncertainty around the cost-effectiveness point 
estimate. However the choice of whether to use RCT data, as one of several information sources to 
populate an economic model, or to undertake a trial-based economic evaluation and subsequent 
model whereby the majority of the model inputs are obtained from the trial, is dependent upon a 
number of factors.  
Situations that would point towards a trial-based economic evaluation being more appropriate 
might include those where costs are largely driven by, or estimated from, the primary outcomes of 
the trial (such as for cardiovascular outcomes or COPD exacerbations). Other factors that point to a 
preference for trial-based evaluations include situations where considerable heterogeneity of costs 
is expected, thereby justifying a more individual patient-specific data collection method, or where 
adherence, only apparent in a more pragmatic trial, may drive costs and outcomes. 
2.4. Is the trial in question a suitable vehicle for an economic evaluation? 
The decision as to whether a given trial is a suitable vehicle for an economic evaluation is based 
upon good trial design that is capable of providing unbiased answers to the clinical question; 
whether current practice (which may be best supportive care) is one of the alternatives being 
compared and that the trial setting allows for generalizable results. Factors to be considered include 
the trial type, relevance of the outcome measures and populations, expected effect size, external 
validity as well as logistical considerations for data collection [8-11]. 
With regards to trial type, explanatory trials seek to identify whether an intervention works under 
ideal conditions (a measure of efficacy) whilst pragmatic trials consider whether an intervention 
works in real-life conditions (a measure of effectiveness). Ideally, trials must be at least partly 
pragmatic and therefore relate to actual clinical practice if they are to be suitable for economic 
analysis. However, in the case of new medicines, most RCTs are explanatory, since they are 
concerned with efficacy (as demanded by regulatory authorities), are typically conducted within 
well-resourced settings, recruit a select sample of patients (e.g. defined by their adherence, co-
morbidity, age) and often measure a short-term surrogate outcome. These do not always contain all 
the elements necessary for economic evaluation, since they may be limited by factors such as lack of 
appropriate comparators, insufficient duration of follow-up particularly of lifelong treatments for 
chronic diseases, inadequate powering for economic outcomes, and poor external validity due to 
limited generalizability to other populations or care settings. These factors may be mitigated by the 
use of modelling, for instance to synthesise an indirect comparison against a relevant comparator or 
to extrapolate treatment effects and costs over a longer time horizon.  
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Pragmatic trials on the other hand have broad inclusion criteria for trial participants, measure 
patient-relevant outcome measures and are thus more suited to inform clinical decision making. 
They are intended to reflect usual practice and are better suited as vehicles for economic evaluation, 
but again modelling is invariably necessary in order to meet the evidential requirements of decision 
makers. However in the absence of such studies (as is normally the case with new medicines) the 
analyst is faced with the challenge of how might effectiveness, and hence cost-effectiveness, be 
predicted from data pertaining to a treatment’s efficacy. Neither explanatory nor pragmatic trials 
are typically sufficient for data on adverse events, especially if these are rare. 
2.5. Trials of public health interventions: A special case? 
Many public health interventions are best described as complex [12]. They have several 
components, and effects depend on the context of delivery, synergistic impact of other socio-
economic factors and general societal trends that are outside the remit of those conducting a trial. 
This makes it difficult to attribute cause and, by contrast to trials of clinical interventions, trials of 
public health interventions are conducted as pragmatic, community-based, and often cluster RCTs. 
Cluster RCTs require appropriate statistical methods of analysis, such as the use of multilevel 
modelling to control for the effect of clustering on outcomes and costs, and other considerations 
required for the sample size calculation, the univariate analysis of incremental costs and outcomes, 
the correlation between individual costs and effects, and the distribution of costs and outcomes 
[13].  
There is a growing literature pertaining to solutions to methodological challenges of conducting 
economic evaluations of public health interventions [14-17]. Fischer et al [18] question the “fit” of 
traditional methods of health technology assessment and preoccupation with evidence-based 
medical decision making to a public health context, arguing that this will inhibit spending decisions 
on public health interventions. They state that many population-focussed public health interventions 
seek to make small changes in behaviour across large populations, and large RCTs with sufficient 
power to detect such changes are impractical or prohibitively expensive. Consequently, many trials 
are underpowered and unable to demonstrate whether public heath interventions are effective. 
However, even if underpowered, such trials can generate point estimates that can serve as inputs to 
economic models.  
Fischer et al [18] propose instead a decision theory approach where decision makers use their prior 
beliefs and experience in a structured Bayesian approach. They suggest that this approach is suitable 
for health improvement programmes such as screening and immunization, behaviour change 
“nudges” like food labelling, government policy on health harming products e.g. taxation and pricing, 
and social and economic policies such as those relating to the environment, housing and education 
that have important health impacts. Such community-level interventions are associated with large 
population-health effects that would not be readily captured in RCTs without the application of 
extremely large sample sizes. Applying a decision-theory approach involves the use of prior belief 
evidence combined with RCT evidence, even if underpowered, with the intent of generating a set of 
informed posterior beliefs about the effectiveness of a public health intervention to be weighed up 
against costs. This approach differs from the standard evidence-based medicine approach which 
relies heavily on RCT evidence. 
6 
 
Trials with embedded “process and economic evaluations” help researchers understand mechanisms 
of change and implications for cost-effectiveness across the socio-economic gradient in society. 
Hence helping to address a key tenet in public health - that of reducing inequalities in health. 
3. Methods for resource use estimation 
Costs are determined by the perspective adopted, and this varies according to the payer, healthcare 
system, and by country. A US study, for example, might take an insurers’ perspective and measure 
direct costs such as hospital stays whereas the preference for a societal perspective in the 
Netherlands might lead to an economic evaluation to estimate indirect costs as well as the broader 
public sector costs of social services, educational and/or criminal justice services etc. In developing 
countries, patients may be asked about coping costs and what assets they have to sell in order to 
fund their treatment. Regardless of which items are to be costed, reliable estimation of resource use 
depends on availability of valid methods of measurement. Methods employed in trial-based 
economic evaluations typically include a combination of one or more of the following: abstraction of 
data from routine medical records (e.g. patient notes, electronic medical records or patient 
administration systems), data collated mainly for the purpose of payment (e.g. hospital episode 
statistics, medicines dispensing data, insurance claims), dedicated sections within case report forms 
and administration of questionnaires to patients [5,19] (Figure 1). The choice of data collection 
method is particularly important to minimise missing values and achieve high level of accuracy.  
Insert Figure 1 here 
3.1. Based on patient recall 
Our experience with DIRUM, the Database of Instruments for Resource Use Measurement, 
(http://www.dirum.org) suggests that patient questionnaires are used extensively in many countries. 
For example, the European version of the widely-used Client Service Receipt Inventory (CSRI) [20] 
has been piloted in Spain, Italy, Denmark and the Netherlands, and found to be an acceptable 
method for collating service receipt and associated data alongside assessment of outcomes in 
patients with schizophrenia [21]. In the UK, methods that are reliant on patient recall are the most 
common for measuring resource use among NIHR-HTA programme-funded trials [5]. This is partly 
due to ease of use compared with the logistic challenges associated with obtaining electronic 
resource use data from local or national databases, and partly because there are no other means of 
collecting certain data such as time off work (productivity costs) or non-medical costs (such as 
transport to/from place of care). Data reliant on patient recall are subject to bias which may 
adversely affect the resulting cost estimates. It is generally accepted that there is an inverse 
relationship between length of recall period and accuracy of data [22] owing to patients forgetting 
specific events and /or their timings. It is difficult to define an optimum recall period, as this is 
context-specific, depending on factors such as the nature of the resource use being asked (which 
might define how memorable the event was), the ability of the respondent to understand what is 
being asked of them, the nature of the illness or disease and the frequency of measurement and /or 
follow-up in relation to patients’ clinical requirements.  
While Brown et al [23] suggested that patients could recall their clinical encounters effectively up to 
3 months after the event, Evans et al [24] suggest recall is in fact related to the saliency or the 
impact of the event on the patient’s life. For example, a recall of 6 months might suffice for 
hospitalisations whereas a shorter time frame would be required for repeated visits to a general 
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practitioner (GP) or community pharmacy. Questionnaires that require recall periods of greater than 
12 months are not recommended [25]. Richards et al [26] highlight the association between age and 
recall bias, advising caution with older patients and suggesting there are disparities, even within 
shorter timeframes of 3 months, on high saliency items such as hospitalisations. It is somewhat 
reassuring that the median recall time frames employed in a sample of 100 UK NIHR-HTA 
programme-funded trials was 3 months (IQR, 0.5 to 6 months) [27]. 
Where the likelihood of comprehension is low (e.g. in children) or cognitive impairment is high, 
researchers may have no alternative but to rely on proxy recall, especially if collecting data on a 
broad spectrum of resource usage to a given costing perspective. Levels of agreement between 
patient and proxy or healthcare record and proxy are not well established [24] although, in palliative 
care, at least, there is some evidence to suggest information that relies on observable aspects of 
resource use can have a good level of agreement between patient and proxy [28].  
3.2. Based on routinely collected data 
In the UK, health and social care is provided by multiple agencies that use different database 
systems, currently with limited record linkage. Routinely collected data such as from hospital patient 
notes and GP records are nonetheless used widely alongside patient and proxy-reported healthcare 
use in trial-based economic evaluations [5]. GP records have traditionally been very diffuse though 
systems such as EMIS-web (https://www.emishealth.com) and the Clinical Practice Research Datalink 
(http://www.cprd.com) provide a basis for more accessible data capture. One limitation in the use of 
GP records relates to the trial setting. When studies recruit patients from a hospital setting, for 
instance, sourcing data from individual GPs can be challenging as patients will be served by many. 
Patients recruited via community pharmacies can be geographically disperse, meaning tracking to 
general practice or hospital can be logistically very challenging. However, the availability of national 
hospital datasets can mitigate this problem. 
Acute inpatient care data for hospitals in England are collated for submission to the Secondary Uses 
Service (SUS) primarily for the purposes of Payment by Results (PbR), planning, commissioning and 
management, but also for audit and research [29]. Similar data are collected within the Patient 
Episode Database for Wales (PEDW) and the Scottish Morbidity Database in Scotland. All use 
Healthcare Resource Groups (HRGs) as a currency; however, whereas bundled HRGs which 
constitute all the elements of care associated with a particular intervention, are nationally agreed 
and can be costed using the national tariff, unbundled HRGs are more reliant on the average unit 
cost to the National Health Service as these are commissioned, priced and paid for at a local level 
[29]. The flow of electronic data is presented in Figure 2, which also highlights data amenable to 
costing purposes.  
The advantages and disadvantages of alternative data sources are listed in Table 1. For example, 
Hospital Episode Statistics (HES) a data warehouse of details of all admissions, outpatient 
appointments and A&E attendances at NHS hospitals in England do not contain unbundled HRGs, 
but do contain operational procedure codes (OPCS) which can be used to generate some unbundled 
HRGs such as those associated with diagnostic imaging or expensive drugs. Perhaps the biggest 
limitation of HES data is that they cannot be used to generate unbundled HRGs for critical care which 
can vary by as much as several thousand pounds per day per HRG. Costing carried out by NHS Trusts 
can also provide patient spell level data using outputs from Patient Level Information and Costing 
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Systems (PLICS). These provide spell HRGs, admission dates and discharge dates, and can also 
identify clinical codes and total costs associated with critical care and expensive drugs although 
these costs tend not to be disaggregated into their unbundled HRGs, as seen in SUS PbR. 
Insert Figure 2 and Table 1 here 
Besides the perspective and methods of resource use data collection, there needs to be 
consideration of the scope of the data being collected to – whether only intervention-related 
resource use data should be collected, or all resource use, remains a moot point. Electronic 
databases offer the advantage of providing often complete and extensive resource-use data, 
allowing for cost effectiveness to be presented at various levels of inclusion of resource use. There 
are disadvantages, however, to accessing routine electronic data, which include the cost, the delay 
between patient exiting a trial and the data becoming available, potential for missing data, and the 
complexity of data management. The prospect of more extensive linked data sources will benefit 
health economists engaged in trial-based evaluations especially if they can ease the burden 
associated with accessing, extracting and interpreting the coding within the data systems in order to 
determine the relevant costs. In Wales there already exists the Secure Anonymised Information 
Linkage (SAIL) databank which uses a matching algorithm for GP care, secondary care and local 
authority social services [30]. A comparable initiative across England, Care.data, is currently under 
development. 
4. Methods for measuring health outcomes 
The conventional view from an economics perspective, that RCTs are mainly an opportunity for 
economic data collection, needs to be challenged. Economists need to be embedded within the trial 
management group and encouraged to lead on SWATs (Studies Within a Trial) to develop novel 
methodologies applicable to trial design, conduct or analysis. Besides costs, there are also 
opportunities for developing and refining health outcome measures. Key to this is the shift towards 
involving patients generally, and ascertaining their preferences, specifically, in patient-reported 
outcome measures of health. 
4.1. Choice of outcome measure 
The choice of economic outcome measure for a trial is dependent on the research question, the 
setting and characteristics of the trial participants. In the UK, NICE favours utilities derived from the 
European Quality of Life – 5 Dimension – 3 Levels (EQ-5D-3L) in adults, though accepts mapped EQ-
5D-3L utilities from other health-related quality of life (HR-QoL) measures in situations where direct 
measurements are not available. A five level version of the EQ-5D (EQ-5D-5L) has been developed 
but as yet no scoring algorithm has been released for calculating utility values. Thus, the established 
EQ-5D-3L is currently more widely used in economic evaluation. In cases where the EQ-5D lacks 
content validity, which considers whether an instrument contains all the domains required to 
measure what it is attempting to measure, NICE suggests that alternative HR-QoL measures may be 
used, but does not explicitly refer to preference-based, disease-specific utility measures.  
Challenges with eliciting patient-reported health outcome data can arise when the study population 
have cognitive limitations, for example dementia or learning difficulties, or when the study 
population involves children and young people. A systematic review of the use of the EQ-5D-3L with 
people with dementia found a satisfactory completion rate for people in the mild to moderate stage 
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of dementia due to its brevity [31]. To achieve a satisfactory completion rate in studies involving 
children and young people, the design of data collection materials e.g. questionnaire, form or diary, 
should be tailored for age. Satisfactory completion rates may be achieved, for example, by adapting 
questionnaire design in terms of colour and personalisation for different age categories [32,33]. 
Alternative validated preference-based utility measures validated for children include the HUI-2, 
CHU9D and AQoL-6D  [34]. 
In cases where trial participants are unable to answer questions themselves, the use of a proxy to 
complete questionnaires on behalf of the participant may be considered. This in turn raises the 
question of whether the proxy should be a family member with direct experience of the participant’s 
health, or a healthcare professional who has a broader experience of the condition. With reference 
to people with dementia, EQ-5D rated quality of life is consistently scored higher by patients than by 
their proxies [31]. Similarly, children and young people may rate their quality of life higher than their 
proxies, such as in the case of diabetes where they respond more positively to the PedsQL-General 
Module, diabetes self-efficacy (PedsQL-Diabetes Module) and their health utility (EQ-5D) than their 
proxies [32]. In the context of clinical trials, it is important to record who is completing proxy 
questionnaires to avoid any uncertainty over whether the questionnaire was completed by the 
family member, carer, healthcare professional or researcher. This may be facilitated by providing 
training and instructions to researchers on how to interview and how to administer questionnaires 
consistently. [35] 
Healthcare interventions may have an HR-QoL impact beyond the index patient, for example on 
family carers. Al-Janabi et al [36] pose the argument that using a HR-QoL measure to assess carer 
quality of life imposes upon them a ‘patient identity’, misinterpreting their role. Their suggested 
solution was to measure care-related QoL instead.  
Use of generic, preference-based utility measures allows for the consistent comparison of results 
across different settings, populations, and interventions; however disease-specific, preference-based 
measures allow a greater degree of sensitivity. By way of example, the epilepsy-specific quality 
adjusted life year (QALY) measure, NEWQOL-6D, was derived from the NEWQOL measure of health-
related quality of life, firstly by psychometric and Rasch analyses to establish the dimension 
structure of NEWQOL and secondly, by valuing the health states generated by the classification 
system using Time Trade Off [37]. The results were modelled to generate a utility score for every 
health state defined by 6 dimensions (worry about attacks; depression; memory; concentration; 
stigma; control). A re-analysis of economic evaluation of an RCT comparing standard versus new 
antiepileptic drugs [38], revealed a different rank ordering of cost-effectiveness based on the 
NEWQOL-6D than with the EQ-5D, suggesting that selection of dimensions of health more relevant 
to epilepsy might affect policy choices. However the increased sensitivity of disease-specific 
preference-based outcome measures is traded against a loss of comparability of utility across 
different interventions and a potential insensitivity to side effects and /or comorbidities [39]. Further 
development of disease-specific utility measures, their comparison against generic instruments and 
impacts on decisions concerning technical and allocative efficiency is warranted. 
Within a trial, QALYs are typically analysed according to treatment allocation; however trials are 
rarely powered to detect differences in QALYs. An alternative is to adopt an event-based approach, 
whereby clinical events (e.g. stroke, fracture, myocardial infarction) are included as covariates in the 
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regression equation [40]. Results allow a utility (decrement) to be attached to clinical events, and 
provide a coefficient (mediated by clinical events) which captures utility differences by trial arm. 
Briggs et al [41] demonstrated that for an RCT where no significant difference in utility was observed 
using a traditional approach, event-based methods resulted in a moderately significant difference 
between treatment groups. This approach is more closely aligned with model-based economic 
evaluations, where utilities are typically attached to health states. 
4.2. Calculating minimally important differences 
Preference surveys and ranking exercises can be used to inform the choice of outcome of most 
importance, however, methods that measure patients’ willingness-to-trade enables researchers to 
profile the impact of differences in health technologies with common characteristics to ascertain the 
most acceptable threshold at which harms and benefits need to be considered (traded).  
Minimally important differences are necessary for calculating the sample sizes of trials to ensure 
adequate powering; however these are typically determined by clinicians, whose views may not 
necessarily align with those of patients.  
Consider an example of a drug which is effective in causing remission of disease symptoms, but is 
associated with dose-dependent toxicity that may reduce survival. A trial using a lower dose is to be 
designed, with survival as the primary outcome, and which requires a minimally important 
difference to calculate the sample size. Using a discrete choice experiment (DCE) to determine 
preferences in the absence of other data, with remission and survival as attributes, the relative 
importance of movements between levels of each attribute can be estimated as the marginal rate of 
substitution (MRS) [42]. This can be used to estimate patients’ maximum acceptable decrease in 
survival, for a given increase in remission. The MRS is calculated as follows: 
MRSremission = βremission/βsurvival 
where βremission and βsurvival are the coefficients for each attribute, respectively. 
Using a known decrease in remission between low and standard dose (∆remission = remissionlow –
remissionstandard dose), the minimum percentage difference in overall survival (= ∆survival) which a 
DCE respondent would be willing to accept (where the utility associated with the lower dose is 
greater than or equal to the utility of standard dose), is estimated as: 
-MRSremission*∆ remission ≤ ∆ survival 
If the difference in survival between treatment groups is less than ∆survival then from a patient’s 
perspective, the treatment option with lower recurrence would be chosen.  
In the case of multiple attributes, this generalises to: 
− ∑ 𝑀𝑅𝑆𝑎𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒(𝑁) ∗ ∆𝑎𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒(𝑁) ≤ ∆𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙
𝑁
1
 
This trade-off between different outcomes of interest provides the point of indifference from the 
respondent’s perspective and therefore represents the minimally important difference in the 
primary outcome measure (probability of survival) between choosing the trial intervention or not.  
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Caveats are drawn from the type of study required to derive this result; sufficient qualitative 
research into the design of the DCE are required to ensure that attributes are meaningful both to the 
patient, and clinically. It is noted that the DCE are estimated with uncertainty, and responses vary 
depending upon an individual patients’ situation and preferences. Indeed, for a given patient, the 
MRS may not be constant along the indifference curve. Notwithstanding these caveats, this method 
may provide a quantitative means of involving patients in the design stage of an RCT, resulting in an 
effect size that is relevant and meaningful to the patient, rather than chosen based solely on 
clinician consensus or in concordance with previous historic trials where the initial effect size may 
have been chosen somewhat more arbitrarily. 
5. Handling data-related methodological challenges 
5.1. Methods of extrapolation 
Trial follow-up periods are typically shorter than the period during which differences in health 
effects and use of healthcare resources between interventions persist. Consequently, time horizon 
bias is a problematic feature in trial-based economic evaluations. Consider two time scales of 
importance; tRCT which refers to the duration of an RCT (the observed period), and tTH which refers to 
the time horizon of an economic evaluation (the unobserved period). In general, an economic 
analysis at tTH requires extrapolation of the incomplete (censored) data from t ≤ tRCT in order to 
generate predictions of health outcomes and costs after the RCT ceases. Multivariable regression-
based statistical models fitted to RCT data allow simple extrapolation for trial participants beyond 
the observed period given information on individual-level characteristics such as age, sex, disease 
history, or the presence of other known risk factors that appear as predictor variables in the model. 
This approach, however, may be limited by the validity of assumptions such as the linear 
dependence of health outcomes on predictor variables or the appropriateness of extrapolating 
associations beyond the trial period, plus factors such as censored (or missing) individual-level data 
or bias arising from loss to follow-up, so such models should be used with caution. 
Other common approaches include the use Markov models, which take the form of dynamic 
discrete-time models represented by difference equations (or, in continuous-time, differential 
equations) or, extrapolating survival/time-to-event data by fitting parametric models to RCT data 
and assuming proportional hazards (PHs) to determine intervention group survival. In the latter case, 
however, PHs becomes an increasingly unreliable assumption as tTH increases towards lifetime 
duration due to additional factors such as age-dependent mortality [43]. Alternatives to parametric 
models for time-to-event data (such as spline-based methods, piecewise modelling, and other semi-
parametric or non-parametric models) have also been proposed [44].  
Whatever the method, robust extrapolation relies on thoughtful model development, reliable 
parameterisation, and intelligent fitting to data; uncertainty in extrapolation increases as the ratio 
tTH/tRCT increases, so the time horizon and time-discounting rates are critical. When fitting models to 
RCT data, fitting to only (stable) data in the observed period that most closely replicates expected 
conditions in the unobserved period, rather than the full dataset, may lead to more efficient use of 
the available evidence [45]. If models used for economic evaluation are underpinned by dynamic 
mechanistic disease models (such as in the case of infectious disease), consideration must be given 
to how the time scales of diseases processes relate to tRCT in order to ensure that model fit is not 
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based on transient model behaviour that will not be representative of long-term disease dynamics 
reached within the unobserved period (Figure 3). 
Insert Figure 3 here 
Model design and parameterisation should be based on underlying assumptions informed by the 
problem (and disease) in hand, which should, in turn, be motivated by factors such as 
pathophysiological processes, clinical and epidemiological knowledge, previous modelling work, 
statistical evidence, and/or desired model complexity. Assimilation of this knowledge unavoidably 
introduces uncertainty in the model construction process, together with uncertainty arising from the 
data itself (such as quality, bias or missing data). Bias in model selection due to (subjective) modeller 
preference also represents a potential source of error.  
The central methodological issue in extrapolation is to understand the robustness of (and confidence 
that should be attached to) long-term model predictions (and economic decisions) given the array of 
structural, parameter, and methodological uncertainties (as well as variability and heterogeneities) 
associated with the modelling process [46]. This question ideally necessitates (a) identifying and 
specifying all uncertainties arising from the modelling process, (b) quantifying (and representing) the 
resultant total uncertainty arising in the economic evaluation associated with extrapolation, and (c) 
assessing which sources of uncertainty most significantly affect the conclusions of the economic 
evaluation, although this 3-step procedure is currently rarely followed in full. Included in the process 
of quantifying uncertainty in model development should be a critique of whether structural 
assumptions in model design for t ≤ tRCT are valid for (and can be trusted to generalise to) t > tRCT; 
examples include consideration of whether new interventions may change in efficacy over time (e.g. 
new antimalarial drugs due to resistance) or whether temporal changes in disease parameters (e.g. 
due to seasonal fluctuations) are important. Structural uncertainty may be addressed using scenario 
analysis or model comparison/averaging [47], but it is important to recognise that good model fit for 
t ≤ tRCT does not guarantee model reliability, accuracy or robustness of assumptions for t > tRCT; if tRCT 
is considerably less than tTH, structurally different models with almost equivalent goodness-of-fit in 
the observed period can produce very different predictions for cost-effectiveness at tTH (see Figure 
4). 
Insert Figure 4 here 
Ultimately, model validation, assessing a model’s accuracy in making predictions for the specific 
purpose of interest, is critical to confidence in the extrapolation process. As a minimum, this should 
include a careful critique of model structure, parameterisation, and problem formulation (in the 
specific context of t > tRCT conditions), but should ideally consider more rigorous validation principles 
including examination of different models addressing the same problem (and assessment of the 
implications for resultant economic evaluations and decision-making), comparison with relevant 
available data from sources beyond those from the RCT used for model fitting, and identification of 
opportunities to compare the predictions of models with observable events and outcomes that may 
occur for t > tRCT (arguably the most desirable form of validation) [48]. Dominant sources of 
uncertainty in the unobserved period may not be the same as those arising in the observed period, 
and the results may depend on the problem in hand, the type of outcomes of interest, and the 
nature of the model itself. 
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5.2. Dealing with missing data 
Missing data is almost unavoidable in clinical trials and can impact on economic evaluations in terms 
of loss of precision and statistical power, which may bias the results such that any consequent 
conclusions made might lead to incorrect policy decisions. Resource use, cost or health outcome 
data derived from patient questionnaires or case report forms are prone to being incomplete, as are 
alternative electronic data sources, such as hospital episode statistics, which also have the potential 
to contain anomalies that are required to be treated as missing data.  
The reporting of missing data in trial-based economic evaluations and the methods used to handle 
missing data are varied and unclear, with sensitivity analysis around the missing data rarely being 
performed [49]. Poor handling of missing data introduces not only the risk of imprecision, loss of 
power and bias, but in addition, missing baseline data becomes problematic when estimating effect 
size [50], leading to challenges in cost-effectiveness analysis when baseline adjustments are 
considered [51]. Sterne et al [52], offer guidance on the reporting of missing data, and the ISPOR 
Task Force report on conducting cost-effectiveness analysis alongside RCTs [53] make explicit 
recommendations on both the analysis and reporting of missing data. The Consolidated Standards of 
Reporting Trials (CONSORT) guidelines require that RCTs report the flow of patients through the trial, 
and the numbers included for analysis [54], however no such clause is included for reporting how 
missing data is analysed [55]. Neither the NICE reference case [7] nor the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) [56] explicitly require the reporting of missing 
data, or give guidance as to how missing data ought to be analysed, although it may be assumed that 
missing data contributes to uncertainty, which is covered by the guidelines  [49]. 
The potential for missing data should be realised at the trial design stage, with procedures 
implemented to minimise wherever possible [57]. Patient questionnaires require careful design and 
piloting, with consideration given as to how, when and where they are administered, as described 
above. With regards to cost data, it may be prudent to explore multiple sources of data, electronic in 
combination with case report forms, so as to have overlap and a secondary source from which to 
replace missing data. 
The mechanism of missing data can classified into three types, missing completely at random 
(MCAR), missing at random (MAR), and missing not at random (MNAR) [58]. Complete case analysis, 
effectively ignoring incomplete data, remains popular for trial data [49,57], but is valid only when 
data are assumed to be MCAR. When the MCAR assumption does not hold, however, the data may 
no longer be representative of the target population, thus compromising external validity [59]. Ad-
hoc methods, such as mean imputation, attempt to address missing data, but are also only valid 
under MCAR. Whilst preserving point estimates, mean imputation attenuates variance, leading to 
artificially small confidence intervals. 
Maximum-likelihood estimation (MLE) methods such as expectation maximisation are valid under 
the less restrictive MAR assumption, however separate MLE models are required for each different 
analysis. Additionally, MLE can be challenging for certain approaches such as generalised linear 
modelling [60]. Multiple imputation (MI) [50] is also valid under MAR, and requires only a single 
model, however other challenges are introduced, as multiple imputed data sets require to be 
analysed, and methodology for pooling results is not always intuitive, often with transforms required 
prior to pooling [61]. Nevertheless, MI has been shown to be robust to departures from normality, in 
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cases of low sample size, and when the proportion of missing data is high [62]. MNAR specific 
methods include the Heckman selection model [63] and pattern mixture models [64], and a novel 
weighting approach adapts MI specifically for data which are MNAR [65]. It is noted however that for 
data which are MNAR, MLE and MI analysed using information relevant covariates often produces 
accurate unbiased results [66,67]. Methods such as these should be applied, where indicated, in 
trial-based economic evaluations. 
5.3. Accounting for non-adherence 
A key issue when generalising the findings of controlled trials to clinical practice is whether efficacy 
can translate to effectiveness; that is, whether the intervention which evidently works, works in 
practice. While adherence encompasses healthcare professionals’ delivery of an intervention, as well 
as following clinical guidelines, a major factor that can impact on a treatment’s effectiveness is the 
effect of patient non-adherence. It is generally recognised that there exists significant differences 
between adherence to (or persistence with) treatments in efficacy trials and routine care. In the case 
of 3-hydroxy-3-methylglutarate-CoA reductase inhibitors (statins) for instance, adherence following 
4-6 years’ follow-up of patients in pivotal trials of secondary prevention ranges from 81% to 99%. 
This contrasts with pragmatic studies conducted in community settings, where adherence ranges 
from 21% to 87% [68]. Differences may be due to intensity of monitoring, frequency of follow-up 
clinic visits and selection of patients, either through protocol specification or through self-selection 
of interested (and hence more adherent) patients. Failure to consider patients’ non-adherence to 
treatments or interventions in economic evaluations can consequently lead to biased estimates of 
cost-effectiveness, with treatments potentially not being as cost-effective as anticipated. Reviews of 
economic evaluations indicate that only a minority assess the impact of non-adherence explicitly 
[69].  
Methods for adjusting effect and cost data for non-adherence and /or premature discontinuation 
are mainly reliant on conventional Markov or decision analytic approach, with assumed reductions in 
benefit and a change in cost, for reductions in adherence [70,71]. Patients who discontinue 
treatment are commonly assumed to experience the benefits and incur the costs associated with a 
placebo group. These strong assumptions may not be valid given that patients may rationally 
discontinue treatment if they experience adverse reactions or perceive no benefit from treatments 
for symptomatic diseases. Placebo data, representing no treatment, may not be available in many 
trials. Alternative approaches require knowledge of baseline covariates that predict adherence for 
each treatment group of the trial. Fischer et al [72] propose a structural mean modelling approach to 
obtain adherence-adjusted estimates for treatment effects in an RCT comparing two active 
treatments; Kadambi et al [69], propose discrete event simulation for economic analyses, as this may 
be more amendable to modelling individuals’ risk of non-adherence, and the link between reduced 
efficacy or increased adverse events and treatment discontinuation. The use of mechanism-based 
modelling, in which individual doses are simulated according to known patterns of adherence, and 
the pharmacokinetic and pharmacodynamics consequences are propagated to estimate the 
reduction in treatment effect, is an alternative approach that may assist in predicting the dilution of 
effect from perfect to typical behaviour of re-medicating [73]. Further research is warranted for 
methods of estimating the impact of variable adherence on the efficacy, and hence cost-
effectiveness, of treatments. 
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6. Multinational trials 
Drug trials are conducted increasingly at multiple centres across many nations. The decision to 
include more than one country for a given trial is typically driven by regulatory requirements, 
achieving the required sample size (e.g. for treatments of a rare disease), or a desire to complete 
within a shorter time frame [74]. Trials conducted in multiple countries may also enhance the 
generalizability of the findings to the participating countries [3,75] and serve to facilitate immediate 
adoption following regulatory approval. However, multinational trials are faced by methodological 
challenges that need to be considered at each stage.  
While multinational trials increase the heterogeneity in the sample in terms of patient 
characteristics and disease severity [3,74,76], it remains common practice for most regulatory 
authorities to accept pooled estimates of clinical efficacy across countries. This is usually based on 
the assumption that the clinical response is unlikely to vary significantly and can therefore be 
considered homogenous [76]. However, difficulties arise when economic evaluations are conducted 
alongside multinational trials, where other sources of heterogeneity become pertinent. Moreover, 
an aggregate estimate of cost-effectiveness (or economic value) would be of limited, if any, value for 
each participating country’s decision makers, where the use of country-specific estimates is usually a 
requirement for reimbursement authorities. 
Costs of care vary widely from one country to another. This variation originates from differences in 
demographics, underlying disease epidemiology and patient mix. However, it is usually the 
differences in the price weights (both absolute and relative) and clinical practice that are the most 
influential [75,76], and these must be taken into account when analysing trial data. Prices may 
themselves influence clinical practice and resource use, for instance with substitution of more costly 
(or less subsidised) resources by cheaper ones. Differences in health care financing mechanisms also 
affect the choice of the perspective from which an economic evaluation is undertaken, be it a 
national health service, private insurer or the patient [35].  
Due consideration should also be given to the choice of outcome measures to be used in the trial, 
the availability of translated and validated versions [77], and the selection of tariffs for preference-
based measures. Differences in clinical practice between countries typically mean that the 
comparator may be less relevant, necessitating alternative or supplementary analysis e.g. using 
indirect comparisons. 
The methods for multinational trial data analysis have been reviewed by Reed et al [74], who 
developed a classification system that combines both the type of analysis used for clinical 
effectiveness and resource use (fully pooled, partially split or fully split) and the costing method (one 
country or multi-country costing). Random-effects/multi-level modelling has been identified as a 
promising approach that offers an intermediate solution between fully split and fully pooled analysis 
and offers country specific estimates without compromising the power of the analysis [78]. In 
choosing an approach, Reed et al [74] recommend health economists need to balance a number of 
issues including, generalisability and transferability of data between countries, awareness of the 
statistical power and consideration of uncertainty within the analysis. 
Researchers engaged in the design and analysis of economic evaluations based on multinational 
trials, are advised to consult relevant guidelines [76]. 
16 
 
7. Conclusions 
This review highlights selective key challenges in the design, conduct, analysis and reporting of trial-
based economic evaluations. It unapologetically focuses on the research interests of the authors, 
and consequently adopts a UK-focus, but through this introduces some concepts and methods that 
have not yet gained mainstream adoption in trial-based economic evaluations. It should serve to 
stimulate debate around the appropriate approaches to best serve the evidential needs of decision 
makers. 
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Figure 1: Methods for measuring resource use and assigning costs within trial-based economic 
evaluations 
 
 
Figure 2: Flow of electronic data in secondary health care in the English National Health Service [29]. 
Cells in paler green represent the key areas where routinely collected data could be utilised for trial-
based economic evaluations. 
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Figure 3: HIV infection dynamics based on the dynamic mechanistic transmission model (and 
parameters) of Keeling and Rohani [79] showing the total AIDS incidence (per year per 1000 
population) across all sexual activity classes. Calculating the cost-effectiveness of a new intervention 
against HIV, based on extrapolating data obtained from an RCT (which typically take place over a 
relatively short timescale), will depend strongly on what phase of the epidemic curve is used for 
disease predictions and the time horizon of interest. If the RCT takes place near the start of a new 
HIV epidemic (when incidence increases approximately exponentially), this will give very different 
estimates of long-term cost-effectiveness compared to estimation in a population where the disease 
has already become endemic (here, after around 60 years). In the context of endemic infections, this 
early rapid growth and subsequent decline in the number of cases is an example of transient model 
behaviour, which differs significantly from the long-term disease dynamics, which, here, reach a 
steady-state. 
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Figure 4: Illustrative example of extrapolating RCT survival data from an observed period (here, one 
year) to a follow-up period of four years using a simple 2-state Markov model, after which an 
economic evaluation of the intervention cost-effectiveness is undertaken. In this case, the Markov 
model consists of two states (‘Well’ and ‘Dead’, with the probability of moving from the former to 
the latter within a time-step given by the survival distribution of interest). Here, monthly simulated 
RCT data is generated from a log-Cauchy distribution and five parametric survival models (gamma, 
log-normal, Dagum, log-logistic and Weibull) are fitted to the RCT data using least-squares and then 
extrapolated using the Markov model to a time horizon of five years. Despite a near identical fit to 
the trial data, estimation of the cost-effectiveness over the follow-up period differs significantly 
depending on the parametric model adopted.  
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Source 
 
Advantages Disadvantages 
Case Notes  Close to source 
 Patient linkable 
 Can use local costs such as cost 
per bed day 
 Limited data 
 Hard to collect if require data 
from many hospitals 
 Have to be transcribed to CRF or 
trial database 
Patient 
Administration 
System 
 Close to source 
 Patient linkable 
 Can use local costs such as cost 
per bed day 
 Limited data 
 Hard to collect if require data 
from many hospitals 
 Practical issues in obtaining data 
from individual Trusts 
Patient-level 
information and 
costing systems 
(PLICS) 
 Detailed patient-level 
information (e.g. HRGs, clinical 
codes) 
 Patient linkable 
 Overall cost per patient per 
spell from hospital perspective 
 Hard to collect if require data 
from many hospitals 
 Delays in data generation due to 
detailed costing being 
undertaken at the end of a 
financial year 
Hospital Episode 
Statistics (HES) 
 Detailed patient-level 
information (e.g. HRGs, clinical 
codes) 
 Patient linkable 
 Shows attendances at other 
hospitals 
 Shows finished consultant 
episodes (FCEs) 
 Does not contain unbundled 
HRGs 
 Unsuitable for critical care 
 Long delays in data availability 
due to data cleansing 
 Tariff information such as 
market forces factors need to be 
linked in 
 Due to changes in management 
and the disbandment of the 
NHS Information Centre, 
information has become harder 
to obtain. 
Secondary Uses 
Service (SUS) 
Payment by Results 
(PbR) 
 Detailed patient-level 
information (e.g. HRGs, clinical 
codes) 
 Contains unbundled HRGs 
 Pseudonymised patient level 
 Tariff information such as 
market forces factors included 
 Not patient linkable 
 
Table 1: Advantages and disadvantages of routinely available data in the National Health Service in 
the UK 
